Transarterial chemoembolization of liver metastases in patients with uveal melanoma
Section snippets
Introduction and purpose
Uveal melanomas represent about 5% of all melanomas [1]. Its dissemination is characterized by a strong tendency of hepatic involvement. Up to 50% of all patients develop metastases, about 87% to the liver, 46% to the lung and 29% to the bones; up to 60% of patients with tumor dissemination suffer from isolated liver involvement [1], [2], [3], [4]. The time interval between primary diagnosis and liver metastases ranges from 5 to 240 months, with a median of 36 months [1], [5].
Spontaneous
Patients
Between july 2001 and december 2006 we treated 14 patients with hepatic metastases secondary to uveal melanoma by hepatic transarterial chemoembolization (TACE). All procedures were in accordance with the ethical standards of the World Medical Association. Gender, age and liver tumor involvement are summarized in Table 1. Interval between the detection of the primary tumor and liver metastases ranged from 1 month to 20 years (mean 48 months). Two to four weeks prior to TACE systemic
Methods
Thirty-four TACE‘s were performed in 14 patients (range: 1–5 treatments per patient, mean: 2.4 treatments). The procedure was repeated with a mean interval of 8 weeks (range: 4–24 weeks). In patients with multiple metastases involving both liver lobes our strategy was to start with the segments containing the largest tumor nodules. To limit side effects, we did not treat more than 3 segments during one session. The intention was to treat all liver segments involved by tumor at least one time
Results
Treatment of all liver segments by at least one TACE was completed in 11 patients. In one patient the segments 4–8 showed metastases during CT and angiography but segment 2 and 3 did not; treatment was performed only in segment 4–8. In two patients metastases in the right liver lobe were treated, however small metastases (<8 mm) of segment 2 and 3 were not treated, because patients did not attend further treatments for individual reasons.
In all patients metastases showed moderate
Discussion
For patients with isolated liver metastases from uveal melanoma hepatic arterial infusion (HAI) and TACE are reasonable palliative treatment options. Cisplatine, carboplatine, fotemustine, melphalan and BCNU have been selected in previous studies for cytostatic drug infusion whereas iodized oil, polyvenylalcohol particles and gelfoam cubes where applied for embolization (Table 3). Cisplatine-based protocols for TACE showed in three of four series response rates varying from 25% to 50% [15], [16]
References (29)
- et al.
Treatment of metastatic uveal melanoma: review and recommendations
Surv Ophthalmol
(1992) - et al.
Bleomycin, vincristine, lomustine,and dacarbacine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
Eur J Cancer
(2003) - et al.
Uveal melanoma: natural history and treatment options for metastatic disease
Melanoma Res
(1999) - et al.
Prognosis in metastatic chorioidal melanoma
South Med J
(1981) Malignant melanomas of the human uvea: twenty-five-year follow-up of cases in Denmark, 1943–1952
Acta Ophthalmol
(1982)- et al.
Therapie des metastasierten malignen Uveamelanoms
Hautarzt
(2001) - et al.
A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma
Arch Ophthalmol
(1983) - et al.
Survival of patients with metastases from uveal melanoma
Ophthalmology
(1991) - et al.
Survival in metastatic ocular melanoma
Cancer
(1983) - et al.
Prognosis and treatment of disseminated uveal melanoma
Cancer
(1983)
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbacine (BOLD), and human leucocyte interferon for metastatic uveal melanoma
Cancer
BOLD + interferon in treatment of metastatic uveal melanoma: first report of active systemic therapy
J Exp Clin Cancer Res
Hepatic arterial chemoembolization for management of metastatic melanoma
Am J Roentgenol
Chemoembolization of hepatic the artery with BCNU for metastatic uveal melanoma: results of a phase II study
Melanoma Res
Cited by (0)
- 1
Tel.: +49 7071 298 3751; fax: +49 7071 29 3765.
- 2
Tel.: +49 7071 298 2087; fax: +49 7071 29 5845.
- 3
Tel.: +49 6151 107 6500; fax: +49 6151 107 6599.